Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IGF2R
REST API REST API
Homo sapiens
IGF2R is differentially expressed in 310 experiments: 134 organism parts: prostate, bone marrow, ... (132 more);, 171 disease states: normal, glioblastoma, ... (169 more);, 106 cell types 443 cell lines 46 compound treatments and 80 other conditions.
Synonyms MPR1, CD222, CIMPR, MPRI, M6P-R
Orthologs IGF2R (Gallus gallus)   igf2r (Danio rerio)   Igf2r (Rattus norvegicus)   Igf2r (Mus musculus)   Q862E4_BOVIN (Bos taurus)   ENSCING00000005133 (Ciona intestinalis)   Lerp (Drosophila melanogaster)   igf2r (Xenopus laevis)   B1H0W0_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transporter activity, endocytic vesicle, transport, protein binding, cytoplasm, membrane, trans-Golgi network transport vesicle, insulin-like growth factor receptor signaling pathway, receptor-mediated endocytosis, membrane fraction, nuclear envelope lumen, insulin-like growth factor binding, lysosomal membrane, integral to plasma membrane, nucleus, receptor activity, mannose binding, endosome, phosphoprotein binding, integral to membrane, cell surface, signal transduction, glycoprotein binding, insulin-like growth factor-activated receptor activity
InterPro Term CIMR, FN_type2_col-bd
UniProt Accession P11717, A0N9R6, A0N9R7
Search EB-eye ENSG00000197081
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HCC1143
2
E-MTAB-37, E-MTAB-62
HCC1937
2
E-MTAB-37, E-MTAB-62
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-GEOD-14990, E-TABM-420
MCF-7
2
E-GEOD-20081, E-GEOD-3529
437 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-2822, E-GEOD-21909, ... (49 experiments)

Factor Value U/D Experiments
monocyte
3
E-GEOD-5099, E-MEXP-583, E-GEOD-22373
mononuclear
2
E-GEOD-26672, E-GEOD-13987
CD4+ T cell
1
2
E-GEOD-16190, E-GEOD-6740, E-MTAB-25
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-26672, E-GEOD-2248
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
cardiac myocyte
1
E-AFMX-5
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (65 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
glioblastoma
1
3
E-GEOD-6014, E-GEOD-4290, E-MTAB-62, E-MTAB-37
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-5550
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
165 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
placebo
2
E-MEXP-1335, E-MEXP-1327
nebivolol
1
E-GEOD-3356
saline
1
E-GEOD-3026
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
Cxcl12
1
E-GEOD-7307
40 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-19246, E-GEOD-20499, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-1045, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-21612, E-GEOD-10315, E-MEXP-1273, E-TABM-263, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-GEOD-20559, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-1956, E-MEXP-2069, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400, E-GEOD-923 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-2487, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-19330, E-GEOD-15811

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.399 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM